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Abstract
Purpose The purpose of the study is to determine the impact
of 13N-ammonia positron emission tomography (PET) myo-
cardial perfusion imaging (MPI) on clinical decision making
and its cost-effectiveness.
Materials and methods One hundred consecutive patients
(28 women, 72 men; mean age 60.9±12.0 years; range 24–
85 years) underwent 13N-ammonia PET scanning (and com-
puted tomography, used only for attenuation correction) to
assess myocardial perfusion in patients with known (n=79)
or suspected (n=8) coronary artery disease (CAD), or for
suspected small-vessel disease (SVD; n=13). Before PET, the
referring physician was asked to determine patient treatment
if PET would not be available. Four weeks later, PET patient
management was reassessed for each patient individually.
Results Before PET management strategies would have
been: diagnostic angiography (62 of 100 patients), diag-
nostic angiography and percutaneous coronary intervention
(PCI; 6 of 100), coronary artery bypass grafting (CABG;
3 of 100), transplantation (1 of 100), or conservative medical
treatment (28 of 100). After PET scanning, treatment strat-
egies were altered in 78 patients leading to: diagnostic
angiography (0 of 100), PCI (20 of 100), CABG (3 of 100),
transplantation (1 of 100), or conservative medical treatment
(76 of 100). Patient management followed the recommen-
dations of PET findings in 97% of the cases. Cost-
effectiveness analysis revealed lower costs of €206/patient
as a result of PET scanning.
Conclusion In a population with a high prevalence of
known CAD, PET is cost-effective and has an important
impact on patient management.
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Introduction
Clinical decisions regarding the need for angioplasty or
bypass surgery are often based on qualitative angiographic
evaluations of coronary lesions. However, it is well known
that coronary anatomy does not accurately reflect the
pathophysiological significance of lesions [1–3], as stenosis
significance depends upon a complex relationship between
coronary pressure, lesion length and shape, the number and
size of branching arteries, and their relationship to the
coronary lesion [1, 4, 5]. Single photon emission computed
tomography (SPECT) and positron emission tomography
(PET) are widely established methods for the evaluation of
the physiological significance of coronary lesions [6–9].
Myocardial perfusion imaging (MPI) with 13N-ammonia
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and PET is considered the clinical ‘gold standard’ for
perfusion [10], and it has been suggested to have a higher
accuracy for the assessment of coronary artery disease
(CAD) compared to SPECT [11–14], which is primarily
due to its higher spatial resolution. Furthermore, 13N-ammonia
MPI enables the quantification of perfusion and thus the
determination of the coronary flow reserve (CFR), a
parameter with high sensitivity and predictive value for
CAD, and it is considered a prerequisite for the detection of
small vessel disease (SVD; [15–17]).
Nonetheless, neither the impact of MPI using PET on
decision making in the daily clinical routine, nor its cost-
effectiveness, have so far been investigated prospectively.
Thus, the objective of the present study was to evaluate the
impact of MPI using PET with 13N-ammonia on clinical
decision-making and to evaluate its cost-effectiveness.
Material and methods
Patients
Between January 2004 and February 2005, 100 consecutive
patients (28 female, 72 male; mean age 60.9±12.0 years;
age range 24–85 years) were prospectively enrolled in the
study and underwent 13N-ammonia MPI on a PET scanner
to rule out suspected CAD (n=8), for further evaluation of
known CAD (n=79), and for diagnosis of suspected small
vessel disease (n=13).
All patients were specifically referred to PET scanning for
clinical indications as mentioned above. SPECT was consid-
ered to be no alternative in suspected SVD (n=13), complex
three-vessel disease (n=62), or patients with a history of two-
vessel disease and suspected progression to multi-vessel-
disease (n=13). In the remaining 12 patients, PET was
considered superior to SPECT (by the referring doctors) to
rule out ischemia, due to its higher reported specificity [11].
Written informed consent was obtained from all patients,
and approval was provided by the local ethics committee.
Study design
Before PET scanning, the referring physician was asked to
determine patient management if MPI would not be available.
Choices were
a) diagnostic angiography,
b) diagnostic angiography and percutaneous coronary
intervention (PCI),
c) coronary artery bypass grafting (CABG),
d) transplantation, or
e) conservative medical treatment with or without anti-
ischemic medication.
Four weeks after PET scanning, patient management was
reevaluated using the same categories mentioned above.
Treatment changes were assessed for each patient individ-
ually. Furthermore, we evaluated whether the chosen
strategy of patient management was “in line” with MPI
findings and the resulting recommendations, assuming that
ischemia would justify PCI, CABG, or antiischemic
medication, while normal findings and scars would justify
conservative management with or without medication or
transplantation. If patient management was “not in line”
with the resulting recommendations, management was
reevaluated with respect to the clinical context.
PET
Imaging was performed on a Discovery LS PET-computed
tomography (CT) scanner (GE Healthcare). This scanner
integrates the Advance PET system, with a 7-mm recon-
structed in-plane resolution, and a four-row helical CT
scanner (LightSpeed Plus). First, a CT scout scan providing
an anteroposterior and lateral view of the chest area was
acquired. This scan was used to localize the field of view
for the following emission and transmission scans. All
patients received a 700- to 900-MBq injection of 13N-
ammonia into a peripheral vein before the start of serial
transaxial tomographic imaging of the heart. Ammonia was
injected during 10 s with a dynamic imaging sequence,
which was previously designed to get a sampling rate
sufficient to measure the tracer bolus and consisted of
twelve 10-s, four 30-s, one 60-s, and two 300-s frames.
Transmission data for photon attenuation correction were
acquired in a nongated CT transmission scan of the chest
area, using the following parameters: scan length, 15 cm;
rotation time, 0.5 s; total scan time, 3.9 s; tube voltage,
140 kV; and slice thickness, 5 mm. Attenuation correction
(AC) was performed using the standard reconstruction soft-
ware of the Discovery LS. For CT-based AC, this software
performs a bilinear conversion of the CT Hounsfield units
into linear attenuation coefficients at the PET energy, as
outlined previously in detail [18]. To achieve accurate image
fusion, the same landmarks were used for repeated scans. MPI
was performed at rest and during standard pharmacologically
induced stress, that is, a 7-min infusion of adenosine, 0.14mg/
min/kg of body weight [19].
Data analysis
Images were transferred to an external workstation (Advantage
Workstation 4.03, GE Healthcare). On reformatted short-axis
slices and polar plots, the left ventricle was subdivided into
a total of six segments (anterior, inferior, posterior, septal,
lateral, apex), as previously published [20]. 13N-ammonia
uptake for each segment at rest and at pharmacologic stress
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was visually graded as “normal” 13N-ammonia uptake, or
“mild” and “severe” reduction of uptake.
Quantitative myocardial blood flow (MBF) and coronary
flow reserve (CFR) were determined in all patients with
suspected SVD using the PMOD software package (PMOD
Technologies). Therefore, a spherical ROI was placed into
the blood pool of the left ventricle. Myocardial and blood
pool time–activity curves were generated from the dynamic
frames and corrected for radioisotope decay. MBF was
estimated by model fitting of the blood pool and myocar-
dial time–activity curves [21]. Corrections for partial
volume and spillover (both accounting for the resolution
distortion) have been performed using the method described
and validated by Hutchins et al. [6], as previously reported
[18, 22]. CFR was calculated as the ratio of hyperemic to
resting MBF.
Cost-effectiveness analysis
We performed a cost-effectiveness analysis to assess direct
costs and benefits as a consequence of the additional appli-
cation of PET to the standard patient management proce-
dures. Cost analysis included all direct costs of standard MPI
with PET and cost of CABG, PCI, and transplantation and
were derived from our accounting department and reflect real
cost for the year 2005, including physician fees. The costs for
conservative medical treatment were not included into the
analysis due to the limited follow-up at the time of analysis.
Costs are expressed in euros.
Statistical Analysis
Quantitative variables were expressed as mean±SD and
categorical variables as frequencies, median (25th, 75th
percentiles), or percentages. All statistical analysis was con-
ducted using SPSS software (SPSS 12.0.1, Chicago, IL, USA).
Results
PET was successfully performed in all patients, and no
complications occurred. All images were of adequate image
quality and suitable for analysis. Baseline characteristics of
the study group are presented in Table 1, displaying a high
prevalence of known CAD.
MPI revealed no perfusion defect in 30 of 100 patients,
while it showed fixed perfusion defects (scar) in 34 of 100
patients and ischemia (with or without scar) in 36 of 100
patients. Segment-based MPI findings are presented in
detail in Table 2.
Overall impact of PET on patient management
If MPI had not been available, the referring physicians would
have chosen the following patient-management strategies:
a) diagnostic angiography in 62 of 100,
b) diagnostic angiography and PCI in 6 of 100,
Table 1 Patient demographics
Demographics Values
Number of patients 100
Age in years (mean±SD) 60.9±12.0
Female gender 28
Male gender 72
Previous coronary angiogram 92
Known CAD (one-, two-, multi-vessel disease) 79 (4, 13, 62)
Suspected small vessel disease 13
No previous coronary angiogram 8a










Previous percutaneous coronary intervention 45
Previous coronary bypass grafting 44
a Patients had a low likelihood for coronary artery disease.
Table 2 PET findings in 100 patients
Segments Reduced uptake at rest Reduced uptake at stress Scar Ischemia Scar and ischemia (n)
Mild (n) Severe (n) Mild (n) Severe (n) Mild (n) Severe (n) Mild (n) Severe (n)
Anterior 14 3 21 6 13 3 8 2 1
posterior 10 5 8 8 7 5 1 0 3
Inferior 13 4 15 9 10 4 5 2 3
Lateral 29 6 27 19 20 6 7 4 9
Septal 1 0 0 1 0 0 0 0 1
Apex 7 8 8 10 6 8 2 1 1
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c) CABG in 3 of 100,
d) transplantation in 1 of 100, or
e) conservative medical management in 28 of 100 patients.
In all patients with suspected SVD (n=13), antiischemic
medication would have been continued.
Patient management after the PET is shown in Fig. 1. It
was influenced in 78% of the study population:
a) diagnostic angiography in 0 of 100,
b) diagnostic angiography and PCI in 20 of 100,
c) CABG in 3 of 100,
d) transplantation in 1 of 100, or
e) conservative medical management in 76 of 100 patients.
Among the patients with suspected SVD, antiischemic
medication was stopped in 9 of 13 patients.
Individual clinical decision-making after PET
Patients with a normal MPI got conservative medical man-
agement (13 of 30; 43%), or conservative (cardiac) medical
management was stopped (rule out CAD or SVD; 16 of 30;
53%), which was considered “in line” with PET results;
whereas one patient (1 of 30; 3%) underwent CABG surgery
despite normal MPI, which was considered “not in line”with
PET results.
In case of a fixed perfusion defect (scar), 94% of the
patients were subsequently treated conservatively (32/34),
which was considered “in line” with PET results. Two
patients with a fixed perfusion defect underwent PCI (2 of
34; 6%) because, compared to previous PET examinations,
the scars were new; therefore, patient management was also
considered “in line” with PET results.
Eighteen of 36 (50%) patients with ischemia underwent
PCI and 2 of 36 (6%) underwent CABG, both of which was
considered “in line” with PET results (Fig. 2). One patient (1
of 36, 3%) with ischemia subsequently underwent trans-
plantation, which was also considered “in line” with PET
results because ischemia was of mild extent, and therefore,
CABG surgery was not considered as a treatment option.
Fifteen of these 36 patients (42%) with ischemia received
conservative medical treatment, which was also considered
“in line”with PET results in 13 patients because (a) ischemia
Fig. 1 Demonstration of changes in patient management after MPI
using PET. Squares at top row represent patient management if MPI
would not have been available (angio Diagnostic angiography, PCI
diagnostic angiography and percutaneous coronary intervention,
CABG coronary artery bypass grafting, Tx transplantation, med. treat.
medical treatment, SVD small vessel disease). White arrows indicate
no changes in patient management; black solid arrows indicate
changes in patient management (numbers given in arrow heads).
Squares at bottom row represent patient management after PET (no
treat. No treatment). Scanning the patient changed management in 78
of 100 patients
Fig. 2 A 71-year-old patient who had had bypass surgery 8 years
before PET was referred to PET for evaluation of myocardial
perfusion because of increasing symptoms of angina pectoris. Because
symptoms were mild, the referring physician would have treated the
patient conservatively with antiischemic medication if MPI would not
have been available. Three axial, one horizontal, and one coronal
image (five images at the bottom) demonstrate decreased 13N-
ammonia uptake at rest in the inferior and apical myocardium,
indicating a scar of mild extent. Five images at the top demonstrate
a further decrease of 13N-ammonia uptake at pharmacological stress in
the inferior and apical myocardium, indicating severe ischemia. Due
to results of PET, patient management was altered, and the patient was
referred to PCI
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was of mild extent, and intervention was considered
unnecessary (seven patients), (b) PCI was technically not
possible and ischemia was considered to be minor for CABG
(two patients), (c) patient rejected PCI (one patient), and (d)
SVD was confirmed (three patients). By contrast, patient
management was considered “not in line” in two patients,
who were referred for preoperative evaluation of CAD and
underwent noncardiac surgery despite severe ischemia.
Redirection of patient management is illustrated in Fig. 3.
In summary, after PET scanning, the management of 3 of
100 patients remained discrepant (“not in line”) to the results
of MPI.
Determination of the presence of small-vessel disease
SVD was confirmed in 4 of 13 patients (31%) referred to
PET. One of them had a visually normal MPI, but a
decreased CFR. Three patients had a reduced global CFR
and minor ischemia on MPI, attributed to localized pro-
nunciation of SVD (n=2) or to the concomitant presence of
macro-vessel disease (n=1) (Fig. 3).
In 9 of 13 patients (69%), SVD was ruled out, and anti-
ischemic medication was stopped. Seven patients had normal
MPI and normal CFR, while two patients had normal CFR, but
a mild myocardial scar, not considered relevant (Fig. 3).
Cost-effectiveness analysis
All patients referred to PET to determine the presence of
SVD were excluded from the cost-effectiveness analysis
because long-term follow-up was not performed, precluding
assessment of long-term costs and/or savings of medical
treatment. For the remaining 87 patients, analysis revealed
lower total savings of €17,910 (€206 per patient) because of
the additional application of PET to the standard patient
management procedures (Table 3).
Discussion
MPI is a widely established method for the noninvasive
evaluation of the pathophysiological significance of coro-
nary lesions in patients with CAD. Our study adds to the
previous knowledge that (a) in a population with a high
prevalence of known CAD, MPI using 13N-ammonia and
PET has an impact on patient management in 78% of the
cases; (b) the additional application of PET is cost-
effective; and (c) patient management followed the recom-
mendations of PET findings in 97% of the cases.
Previous clinical studies [23, 24] have analyzed the in-
fluence of 18F-fluorodeoxyglucose PET myocardial viabil-
Fig. 3 Demonstration of changes in patient management with respect
to the results of MPI with PET. Squares at top row represent patient
management if MPI would not have been available (angio Diagnostic
angiography, PCI diagnostic angiography and percutaneous coronary
intervention, CABG coronary artery bypass grafting, Tx transplanta-
tion, med. treat. medical treatment, SVD small vessel disease). Squares
in the second row represent MPI findings for each subgroup. Patient
management followed the recommendations of PET findings in 97
cases (white arrows) and did not follow the recommendations of PET
in 3 cases (black arrows). Squares at bottom row represent patient


















6 20 14 48,860
CABG 3 3 0 0
transplantation 1 1 0 0
Medical
treatmentc
15 63 48 0
n/ad 13 13
PETe 0 87 87 82,650
Total € −17,910
a Costs of diagnostic angiography in our hospital including 1 day
hospital stay: €2,410/patient
b Costs of diagnostic angiography percutaneous coronary intervention
(PCI) in our hospital including one day hospital stay: €3,490/patient
c Costs of conservative medical therapy were not included into the
cost-effectiveness analysis
d Patients referred for the evaluation of small-vessel disease were not
included into the cost-effectiveness analysis because PET is the
accepted reference standard for diagnosis
e Costs of PET in our department: €950/patient
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ity examinations on patient management and found an
impact in 57–68% of patients. However, search for viability
must, by its nature, remain confined to a highly selected
population of CAD patients with a history of myocardial
infarction. By contrast, our study using PET for the as-
sessment of myocardial perfusion in a consecutive, unse-
lected patient population yielded an impact on patient
management in 78% of patients.
Moreover, 97% of treatment strategies were in concor-
dance with the results from PET scanning. This underlines
the clinical value of MPI with PET. We found only 1% of
patients who underwent CABG despite normal PET MPI,
comparing favorably with the 3–4% reported in retrospec-
tive studies with SPECT MPI in patients with unknown
CAD [25, 26]. Conversely, the proportion of patients in our
study who underwent PCI or CABG after detection of
ischemia was 56%, lying well within the range of 36–60%
reported in previous studies [25, 26].
In patients with unknown CAD, an additional MPI using
SPECT followed by selective coronary angiography has been
shown to be more cost-effective compared with a direct
catheterization-first strategy [27]. In our study, we found that
the additional application of PET to the standard patient
management procedures is also cost-effective in a patient
population with a high prevalence of known CAD because
direct coronary angiographic strategies can frequently be
avoided. This cost-effectiveness would be maintained even
with an increase in PET costs by up to 20%. So far, the routine
use of PET has not been accepted as a standard forMPI inmany
centers and health care systems despite its higher diagnostic
accuracy compared to SPECT, as reported in the ACC/AHA/
ASNC guidelines of nuclear cardiology [11]. The latter par-
ticularly document a superior specificity of PET. This most
likely translates into a higher cost-effectiveness of PET com-
pared to SPECT, as recently reported by Merighe et al. [28].
MPI using PET is the accepted reference standard for the
diagnosis of SVD [29]. In our study population, SVD was
ruled out in 69% of patients with suspected SVD, and
antiischemic medical management was consecutively stopped,
which most likely would further improve the long-term cost-
effectiveness of the method, although this aspect was not
incorporated into our analysis.
We acknowledge the following limitations to our study. We
did not assess how many and which alternative noninvasive
tests for ischemia would have been chosen if PET would not
have been available, as PET was selected deliberately by the
referring physician as the best choice. Therefore, we cannot
comment on the performance of alternative options. We did
not perform a long-term clinical patient follow-up to evaluate
whether the impact of PET on patient management leads to a
prognostic benefit. However, such benefit has been reported
for MPI SPECT in many studies [11], and it appears
reasonable to assume similar performance of PET MPI. As a
further potential limitation, we did not include in our cost-
effectiveness calculation the fact that some patients planned
for angiography may possibly have ended with PCI. This may
have lead to an underestimation of the cost-effectiveness of
PET, further strengthening our results.
Furthermore, costs for medical management were not
included, due to the limited follow-up at the time of
analysis. However, as standard medical treatment in CAD
patients would not differ largely between different strategy
groups, any change of strategy would only cause minor
changes in costs for medication. Finally, we excluded 13
patients referred to PET for the evaluation of SVD because
PET is the accepted reference standard for diagnosis, and
additional patient management procedures cannot be
expected, regardless of the results of PET.
Conclusions
In a population with a high prevalence of known CAD, PET
is cost-effective and has an important impact on patient
management, while patient management follows the recom-
mendations of PET findings in 97% of the cases.
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